Response Genetics, Inc. is a life sciences company engaged in the research and development of clinical diagnostic tests for cancer. The Company generates revenues primarily from sales of its ResponseDX diagnostic tests. The Company focuses on commercialization of its ResponseDX tests; developing additional diagnostic tests for assessing the risk of cancer recurrence, prediction of chemotherapy response and tumor classification in cancer patients, and expanding its testing services business by pursuing new technologies through collaborations and in-licensing to expand its business. It offers its ResponseDX test services nationwide. The Company offers tests for non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and gastric and gastroesophageal (GE), and melanoma cancer patients� tumor tissue specimens through its ResponseDX: Lung, ResponseDX: Colon and ResponseDX: Gastric test suites and ResponseDX: Melanoma.